30 closest matches · ranked by relevance
Pro-opiomelanocortin (POMC) Deficiency Obesity
Primary: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) — 80.0 percentage of participants — p=<0.0001
Bardet-Biedl Syndrome · POMC Deficiency Obesity · PCSK1 Deficiency Obesity
Primary: Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52 — 85.7; 80.0 percentage of participants
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
Leptin Receptor Deficiency Obesity
Primary: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) — 45.5 percentage of participants — p=0.0001
Prader-Willi Syndrome
Primary: Change in Weight — -.5 kg — p=.07
Genetic Obesity · Obesity · Obesity Due to Melanocortin 4 Receptor Deficiency
Primary: Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment — 6; 3; 7; 7 Participants
Prader-Willi Syndrome · Hyperphagia
Primary: Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT) — -6.08; -6.64 score on a scale
Hypothalamic Obesity
Primary: Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment — 88.9 percentage of participants — p=<0.0001
Craniopharyngioma · Hypothalamic Obesity
Primary: Weight Loss — 88.3; 91.9; 1.2; 0.9 kg — p=0.92
Genetic Obesity
Primary: Stage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1 — 49; 0; 0; 2 Participants
Obesity
Primary: Number of Participants Who Reported Nausea at 10 Minutes Post Treatment — 17; 18 Participants
Obesity · Sarcopenic Obesity · Sarcopenia
Primary: Change in Body Weight — 0.54; 0.04 Kilograms
Bardet Biedl Syndrome (BBS) · Alström Syndrome (AS)
Primary: Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort — 32.3 percentage of…
Trifunctional Protein Deficiency
Primary: An Outcome of This Study is the Difference in Percent Body Fat (%BF) Between Subjects With a Long-chain Fatty Acid Oxidation Disorder and Normal Controls. — 31.8; 27.2…
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
Obesity Associated With Defects in Leptin-melanocortin Pathway
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 198 Participants
Prader-Willi Syndrome
Primary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) - Period 2 — 4; 11; 6; 11 Participants
Obesity
Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL
Obesity
Primary: Change in Body Weight From Baseline to 12 Months — 1.09; 1.55 lbs
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Obesity · Metabolic Syndrome · Diabetes
Primary: Weight — NA lbs
Obesity
Primary: Peak Growth Hormone (GH) on the GH Stimulation Test — 40.1; 25.2 ng/ml — p=<0.05
Obesity
Primary: Change in Total Body Weight — -7.7; -6.5 percent change
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
Hypothalamic Obesity
Primary: BMI Change — -0.77 kg/m^2 — p=.05
Hypothalamic Obesity
Primary: Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². — 1.7; 3.5 percent change from baseline — p=0.40
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
Obesity
Primary: Intentions to Lose Weight - Effect of Study Arm on Outcomes — 3.06; 3.37; 3.26; 3.26 units on a scale — p=.0150
Obesity · Healthy Volunteers · Overweight
Primary: Correlation Between Striatal D2 Receptor Binding Potential (D2BP) as Measured by [18F]Fallypride and [11C]Raclopride Time-activity Curves — 0.468 Correlation Coefficient
Obesity
Primary: Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1) — 4.1; 3.6 IU/L